Skip to main content

Articles

Page 22 of 32

  1. Recent evidence derived from functional magnetic resonance imaging (fMRI) studies suggests that functional hubs (i.e., highly connected brain regions) are important for mental health. We found recently that gl...

    Authors: Nicolai Franzmeier, Julia Hartmann, Alexander N. W. Taylor, Miguel Á. Araque-Caballero, Lee Simon-Vermot, Lana Kambeitz-Ilankovic, Katharina Bürger, Cihan Catak, Daniel Janowitz, Claudia Müller, Birgit Ertl-Wagner, Robert Stahl, Martin Dichgans, Marco Duering and Michael Ewers
    Citation: Alzheimer's Research & Therapy 2018 10:28
  2. Dementia due to Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB) are the two most common neurodegenerative causes of dementia. They commonly occur together, especially in older people, but clinical...

    Authors: Alan J. Thomas, Fariba Mahin-Babaei, Mohammad Saidi, Debbie Lett, John Paul Taylor, Lauren Walker and Johannes Attems
    Citation: Alzheimer's Research & Therapy 2018 10:27
  3. The underlying mechanism of brain glucose hypometabolism, an invariant neurodegenerative feature that tightly correlates with cognitive impairment and disease progression of Alzheimer’s disease (AD), remains e...

    Authors: Shaoming Sang, Xiaoli Pan, Zhichun Chen, Fan Zeng, Shumei Pan, Huimin Liu, Lirong Jin, Guoqiang Fei, Changpeng Wang, Shuhua Ren, Fangyang Jiao, Weiqi Bao, Weiyan Zhou, Yihui Guan, Yiqiu Zhang, Hongcheng Shi…
    Citation: Alzheimer's Research & Therapy 2018 10:26
  4. Neuroinflammation has gained increasing attention as a potential contributing factor in Alzheimer’s disease (AD) pathology. A clinical cerebrospinal fluid biomarker capable of monitoring this process during th...

    Authors: Frederic Brosseron, Andreas Traschütz, Catherine N. Widmann, Markus P. Kummer, Pawel Tacik, Francesco Santarelli, Frank Jessen and Michael T. Heneka
    Citation: Alzheimer's Research & Therapy 2018 10:25
  5. The phosphodiesterase (PDE) 7 inhibitor S14 is a cell-permeable small heterocyclic molecule that is able to cross the blood–brain barrier. We previously found that intraperitoneal treatment with S14 exerted ne...

    Authors: Fernando Bartolome, Macarena de la Cueva, Consuelo Pascual, Desiree Antequera, Tamara Fernandez, Carmen Gil, Ana Martinez and Eva Carro
    Citation: Alzheimer's Research & Therapy 2018 10:24
  6. Survival after dementia diagnosis varies considerably. Previous studies were focused mainly on factors related to demographics and comorbidity rather than on Alzheimer’s disease (AD)-related determinants. We s...

    Authors: Hanneke F. M. Rhodius-Meester, Hilkka Liedes, Ted Koene, Afina W. Lemstra, Charlotte E. Teunissen, Frederik Barkhof, Philip Scheltens, Mark van Gils, Jyrki Lötjönen and Wiesje M. van der Flier
    Citation: Alzheimer's Research & Therapy 2018 10:23
  7. Simultaneous consideration of two neuropathological traits related to Alzheimer’s disease (AD) has not been attempted in a genome-wide association study.

    Authors: Jaeyoon Chung, Xiaoling Zhang, Mariet Allen, Xue Wang, Yiyi Ma, Gary Beecham, Thomas J. Montine, Steven G. Younkin, Dennis W. Dickson, Todd E. Golde, Nathan D. Price, Nilüfer Ertekin-Taner, Kathryn L. Lunetta, Jesse Mez, Richard Mayeux, Jonathan L. Haines…
    Citation: Alzheimer's Research & Therapy 2018 10:22
  8. A growing number of pharmacological and nonpharmacological trials have been performed to test the efficacy of approved or experimental treatments in Alzheimer disease (AD) and mild cognitive impairment (MCI). ...

    Authors: Elisa Canu, Elisabetta Sarasso, Massimo Filippi and Federica Agosta
    Citation: Alzheimer's Research & Therapy 2018 10:21
  9. The prevalence of dementia with Lewy bodies (DLB) and dementia in Parkinson’s disease (PDD) in routine clinical practice is unclear. Prevalence rates observed in clinical and population-based cohorts and neuro...

    Authors: Joseph P. M. Kane, Ajenthan Surendranathan, Allison Bentley, Sally A. H. Barker, John-Paul Taylor, Alan J. Thomas, Louise M. Allan, Richard J. McNally, Peter W. James, Ian G. McKeith, David J. Burn and John T. O’Brien
    Citation: Alzheimer's Research & Therapy 2018 10:19
  10. Current approved drugs for Alzheimer’s disease (AD) only attenuate symptoms, but do not cure the disease. The pirinixic acid derivate MH84 has been characterized as a dual gamma-secretase/proliferator activate...

    Authors: Maximilian Pohland, Maren Pellowska, Heike Asseburg, Stephanie Hagl, Martina Reutzel, Aljoscha Joppe, Dirk Berressem, Schamim H. Eckert, Mario Wurglics, Manfred Schubert‐Zsilavecz and Gunter P. Eckert
    Citation: Alzheimer's Research & Therapy 2018 10:18
  11. Alzheimer’s disease (AD) is a complex neurodegenerative disease, and genetic differences may mediate neuronal degeneration. In humans, a single-nucleotide polymorphism in the B-cell chronic lymphocytic leukemi...

    Authors: Chiung-Chih Chang, Ya-Ting Chang, Chi-Wei Huang, Shih-Jen Tsai, Shih-Wei Hsu, Shu-Hua Huang, Chen-Chang Lee, Wen-Neng Chang, Chun-Chung Lui and Chia-Yi Lien
    Citation: Alzheimer's Research & Therapy 2018 10:17
  12. Animal models of Alzheimer’s disease (AD) are essential to understanding the disease progression and to development of early biomarkers. Because AD has been described as a disconnection syndrome, magnetic reso...

    Authors: Emma Muñoz-Moreno, Raúl Tudela, Xavier López-Gil and Guadalupe Soria
    Citation: Alzheimer's Research & Therapy 2018 10:16
  13. Deep phenotyping and longitudinal assessment of predementia at-risk states of Alzheimer’s disease (AD) are required to define populations and outcomes for dementia prevention trials. Subjective cognitive decli...

    Authors: Frank Jessen, Annika Spottke, Henning Boecker, Frederic Brosseron, Katharina Buerger, Cihan Catak, Klaus Fliessbach, Christiana Franke, Manuel Fuentes, Michael T. Heneka, Daniel Janowitz, Ingo Kilimann, Christoph Laske, Felix Menne, Peter Nestor, Oliver Peters…
    Citation: Alzheimer's Research & Therapy 2018 10:15
  14. Despite a tremendous amount of information on the role of amyloid in Alzheimer’s disease (AD), almost all clinical trials testing this hypothesis have failed to generate clinically relevant cognitive effects.

    Authors: Hugo Geerts, Athan Spiros and Patrick Roberts
    Citation: Alzheimer's Research & Therapy 2018 10:14
  15. Accumulating evidence indicates that Tau pathology can spread from neuron to neuron by intake and coaggregation of the hyperphosphorylated Tau (p-Tau) seeds with the host neuron protein. Thus, clearance of Tau...

    Authors: Chun-ling Dai, Wen Hu, Yunn Chyn Tung, Fei Liu, Cheng-Xin Gong and Khalid Iqbal
    Citation: Alzheimer's Research & Therapy 2018 10:13
  16. Immunotherapy targeting the amyloid-β (Aβ) peptide is a promising strategy for the treatment of Alzheimer’s disease (AD); however, none of the active or passive vaccines tested have been demonstrated to be eff...

    Authors: Ana-María Lacosta, María Pascual-Lucas, Pedro Pesini, Diego Casabona, Virginia Pérez-Grijalba, Iván Marcos-Campos, Leticia Sarasa, Jesus Canudas, Hassnae Badi, Inmaculada Monleón, Itziar San-José, Josep Munuera, Octavio Rodríguez-Gómez, Carla Abdelnour, Asunción Lafuente, Mar Buendía…
    Citation: Alzheimer's Research & Therapy 2018 10:12
  17. Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by deposition of amyloid plaques and disruption of neural circuitry, leading to cognitive decline. Animal models of AD deposit senile plaq...

    Authors: Guillaume J. Pagnier, Ksenia V. Kastanenka, Miwon Sohn, Sangzin Choi, Song-hyen Choi, HyeYeon Soh and Brian J. Bacskai
    Citation: Alzheimer's Research & Therapy 2018 10:11
  18. Oligomeric forms of amyloid-β (Aβ) and tau are increasing being recognized as key toxins in the pathogenesis of Alzheimer’s disease (AD).

    Authors: Fernando Goñi, Mitchell Martá-Ariza, Krystal Herline, Daniel Peyser, Allal Boutajangout, Pankaj Mehta, Eleanor Drummond, Frances Prelli and Thomas Wisniewski
    Citation: Alzheimer's Research & Therapy 2018 10:10
  19. Kallikrein 6 (KLK6) is known to be an age-related protease expressed at high levels in the central nervous system. It was previously shown to be involved in proteolysis of extracellular proteins implicated in ...

    Authors: Kalicharan Patra, Antoninus Soosaipillai, Sigrid Botne Sando, Camilla Lauridsen, Guro Berge, Ina Møller, Gøril Rolfseng Grøntvedt, Geir Bråthen, Ilijana Begcevic, Simon Moussaud, Lennart Minthon, Oskar Hansson, Eleftherios P. Diamandis, Linda R. White and Henrietta M. Nielsen
    Citation: Alzheimer's Research & Therapy 2018 10:9
  20. Cerebrospinal fluid (CSF) neurofilament light (NfL) is a reliable marker of neuro-axonal damage in different neurological disorders that is related to disease severity. To date, all recent studies performed in...

    Authors: Lorenzo Gaetani, Kina Höglund, Lucilla Parnetti, Fani Pujol-Calderon, Bruno Becker, Paolo Eusebi, Paola Sarchielli, Paolo Calabresi, Massimiliano Di Filippo, Henrik Zetterberg and Kaj Blennow
    Citation: Alzheimer's Research & Therapy 2018 10:8
  21. In this paper, we describe the clinical and neuropathological findings of nine members of the Belgian progranulin gene (GRN) founder family. In this family, the loss-of-function mutation IVS1 + 5G > C was identif...

    Authors: Anne Sieben, Sara Van Mossevelde, Eline Wauters, Sebastiaan Engelborghs, Julie van der Zee, Tim Van Langenhove, Patrick Santens, Marleen Praet, Paul Boon, Marijke Miatton, Sofie Van Hoecke, Mathieu Vandenbulcke, Rik Vandenberghe, Patrick Cras, Marc Cruts, Peter Paul De Deyn…
    Citation: Alzheimer's Research & Therapy 2018 10:7
  22. Cognitive screeners are imperative for early diagnosis of dementia. The Visual Cognitive Assessment Test (VCAT) is a language-neutral, visual-based test which has proven useful for a multilingual population in...

    Authors: Levinia Lim, Tze Pin Ng, Anam Paulus Ong, Maw Pin Tan, Alvin Rae Cenina, Qi Gao, Adeline Ng and Nagaendran Kandiah
    Citation: Alzheimer's Research & Therapy 2018 10:6
  23. We investigated whether a panel of 12 potential novel biomarkers consisting of proteins involved in synapse functioning and immunity would be able to distinguish patients with Alzheimer’s disease (AD) and pati...

    Authors: Flora H. Duits, Gunnar Brinkmalm, Charlotte E. Teunissen, Ann Brinkmalm, Philip Scheltens, Wiesje M. Van der Flier, Henrik Zetterberg and Kaj Blennow
    Citation: Alzheimer's Research & Therapy 2018 10:5
  24. Given the complex and progressive nature of Alzheimer’s disease (AD), a precision medicine approach for diagnosis and treatment requires the identification of patient subgroups with biomedically distinct and a...

    Authors: Nophar Geifman, Richard E. Kennedy, Lon S. Schneider, Iain Buchan and Roberta Diaz Brinton
    Citation: Alzheimer's Research & Therapy 2018 10:4
  25. Neurofilament light chain protein (NfL) is a surrogate biomarker of neurodegeneration that has never been systematically tested, either alone or in combination with other biomarkers, in atypical/rapidly progre...

    Authors: Samir Abu-Rumeileh, Sabina Capellari, Michelangelo Stanzani-Maserati, Barbara Polischi, Paolo Martinelli, Paola Caroppo, Anna Ladogana and Piero Parchi
    Citation: Alzheimer's Research & Therapy 2018 10:3
  26. The MAPT c.1216C > T (p.Arg406Trp; R406W) mutation is a known cause of frontotemporal dementia with Parkinsonism linked to chromosome 17 tau with Alzheimer’s disease-like clinical features.

    Authors: Emil Ygland, Danielle van Westen, Elisabet Englund, Rosa Rademakers, Zbigniew K. Wszolek, Karin Nilsson, Christer Nilsson, Maria Landqvist Waldö, Irina Alafuzoff, Oskar Hansson, Lars Gustafson and Andreas Puschmann
    Citation: Alzheimer's Research & Therapy 2018 10:2
  27. Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia in the elderly population. In this study, we used the APP/PS1 transgenic mouse model to explore the fe...

    Authors: Jelle Praet, Nikolay V. Manyakov, Leacky Muchene, Zhenhua Mai, Vasilis Terzopoulos, Steve de Backer, An Torremans, Pieter-Jan Guns, Tom Van De Casteele, Astrid Bottelbergs, Bianca Van Broeck, Jan Sijbers, Dirk Smeets, Ziv Shkedy, Luc Bijnens, Darrel J. Pemberton…
    Citation: Alzheimer's Research & Therapy 2018 10:1
  28. Cerebrovascular disease (CVD) and amyloid-β (Aβ) often coexist, but their influence on neurodegeneration and cognition in predementia stages remains unclear. We investigated the association between CVD and Aβ ...

    Authors: Isabelle Bos, Frans R. Verhey, Inez H.G.B. Ramakers, Heidi I. L. Jacobs, Hilkka Soininen, Yvonne Freund-Levi, Harald Hampel, Magda Tsolaki, Åsa K. Wallin, Mark A. van Buchem, Ania Oleksik, Marcel M. Verbeek, Marcel Olde Rikkert, Wiesje M. van der Flier, Philip Scheltens, Pauline Aalten…
    Citation: Alzheimer's Research & Therapy 2017 9:101

    The Correction to this article has been published in Alzheimer's Research & Therapy 2018 10:56

  29. Little is known about factors influencing progression from mild cognitive impairment to Alzheimer’s dementia. A potential role of environmental chemicals and specifically of selenium, a trace element of nutrit...

    Authors: Marco Vinceti, Annalisa Chiari, Marcel Eichmüller, Kenneth J. Rothman, Tommaso Filippini, Carlotta Malagoli, Jennifer Weuve, Manuela Tondelli, Giovanna Zamboni, Paolo F. Nichelli and Bernhard Michalke
    Citation: Alzheimer's Research & Therapy 2017 9:100
  30. In patients with amyloid-positive mild cognitive impairment (MCI), neurodegenerative biomarkers such as medial temporal lobe atrophy (MTA) are useful to predict disease progression to dementia. Although poster...

    Authors: Jung-Min Pyun, Young Ho Park, Hang-Rai Kim, Jeewon Suh, Min Ju Kang, Beom Joon Kim, Young Chul Youn, Jae-Won Jang and SangYun Kim
    Citation: Alzheimer's Research & Therapy 2017 9:99
  31. Soluble amyloid-β (Aβ) oligomers are the major toxic substances associated with the pathology of Alzheimer’s disease (AD). The ability to measure Aβ oligomer levels in the blood would provide simple and minima...

    Authors: Min Jeong Wang, SangHak Yi, Jee-young Han, So Young Park, Jae-Won Jang, In Kook Chun, Sang Eun Kim, Byoung Sub Lee, Gwang Je Kim, Ji Sun Yu, Kuntaek Lim, Sung Min Kang, Young Ho Park, Young Chul Youn, Seong Soo A. An and SangYun Kim
    Citation: Alzheimer's Research & Therapy 2017 9:98
  32. The progress we have made in understanding Alzheimer’s disease (AD) pathogenesis has led to the identification of several novel pathways and potential therapeutic targets. Rho GTPases have been implicated as c...

    Authors: Byron J. Aguilar, Yi Zhu and Qun Lu
    Citation: Alzheimer's Research & Therapy 2017 9:97
  33. The aim of this study was to compare the binding properties of several tau positron emission tomography tracers—THK5117, THK5351, T807 (also known as AV1451; flortaucipir), and PBB3—head to head in the same hu...

    Authors: Laetitia Lemoine, Per-Göran Gillberg, Marie Svedberg, Vladimir Stepanov, Zhisheng Jia, Jinghai Huang, Sangram Nag, He Tian, Bernardino Ghetti, Nobuyuki Okamura, Makoto Higuchi, Christer Halldin and Agneta Nordberg
    Citation: Alzheimer's Research & Therapy 2017 9:96
  34. Gantenerumab is a fully human monoclonal antibody that binds aggregated amyloid-β (Aβ) and removes Aβ plaques by Fc receptor-mediated phagocytosis. In the SCarlet RoAD trial, we assessed the efficacy and safet...

    Authors: Susanne Ostrowitzki, Robert A. Lasser, Ernest Dorflinger, Philip Scheltens, Frederik Barkhof, Tania Nikolcheva, Elizabeth Ashford, Sylvie Retout, Carsten Hofmann, Paul Delmar, Gregory Klein, Mirjana Andjelkovic, Bruno Dubois, Mercè Boada, Kaj Blennow, Luca Santarelli…
    Citation: Alzheimer's Research & Therapy 2017 9:95

    The Correction to this article has been published in Alzheimer's Research & Therapy 2018 10:99

  35. Biomarkers such as amyloid imaging are increasingly used for diagnosis in the early stages of Alzheimer’s disease. Very few studies have examined this from the perspective of the patient. To date, there is onl...

    Authors: Gwendolien Vanderschaeghe, Jolien Schaeverbeke, Rose Bruffaerts, Rik Vandenberghe and Kris Dierickx
    Citation: Alzheimer's Research & Therapy 2017 9:92
  36. Alzheimer’s disease (AD) is the most common type of dementia, affecting one in eight adults over 65 years of age. The majority of AD cases are sporadic, with unknown etiology, and only 5% of all patients with ...

    Authors: Anna Ochalek, Balázs Mihalik, Hasan X. Avci, Abinaya Chandrasekaran, Annamária Téglási, István Bock, Maria Lo Giudice, Zsuzsanna Táncos, Kinga Molnár, Lajos László, Jørgen E. Nielsen, Bjørn Holst, Kristine Freude, Poul Hyttel, Julianna Kobolák and András Dinnyés
    Citation: Alzheimer's Research & Therapy 2017 9:90
  37. Clusterin and beta-amyloid (Aβ) are involved in the pathogenesis of Alzheimer’s disease (AD). The clinical significance of plasma clusterin and Aβ in AD progression remains controversial.

    Authors: Jung-Lung Hsu, Wei-Ju Lee, Yi-Chu Liao, Shuu-Jiun Wang and Jong-Ling Fuh
    Citation: Alzheimer's Research & Therapy 2017 9:91
  38. Minimally invasive specific biomarkers of neurodegenerative diseases (NDs) would facilitate patient selection and disease progression monitoring. We describe the assessment of circulating brain-enriched microR...

    Authors: Kira S. Sheinerman, Jon B. Toledo, Vladimir G. Tsivinsky, David Irwin, Murray Grossman, Daniel Weintraub, Howard I. Hurtig, Alice Chen-Plotkin, David A. Wolk, Leo F. McCluskey, Lauren B. Elman, John Q. Trojanowski and Samuil R. Umansky
    Citation: Alzheimer's Research & Therapy 2017 9:89
  39. African Americans have been reported to have a higher prevalence of Alzheimer’s disease (AD) than Caucasians, but etiology-specific AD biomarkers have not been systematically analyzed in older African American...

    Authors: Jennifer C. Howell, Kelly D. Watts, Monica W. Parker, Junjie Wu, Alexander Kollhoff, Thomas S. Wingo, Cornelya D. Dorbin, Deqiang Qiu and William T. Hu
    Citation: Alzheimer's Research & Therapy 2017 9:88
  40. This commentary discusses the implications of disease-modifying treatments for Alzheimer’s disease which seem likely to appear in the next few years and results from a meeting of British experts in neurodegene...

    Authors: Craig W. Ritchie, Tom C. Russ, Sube Banerjee, Bob Barber, Andrew Boaden, Nick C. Fox, Clive Holmes, Jeremy D. Isaacs, Ira Leroi, Simon Lovestone, Matt Norton, John O’Brien, Jim Pearson, Richard Perry, James Pickett, Adam D. Waldman…
    Citation: Alzheimer's Research & Therapy 2017 9:85

    The Correction to this article has been published in Alzheimer's Research & Therapy 2018 10:73

  41. From earlier studies it is known that the APOE ε2/ε3/ε4 polymorphism modulates the concentrations of cerebrospinal fluid (CSF) beta-amyloid1–42 (Aβ42) in patients with cognitive decline due to Alzheimer’s disease...

    Authors: Ronald Lautner, Philip S. Insel, Tobias Skillbäck, Bob Olsson, Mikael Landén, Giovanni B. Frisoni, Sanna-Kaisa Herukka, Harald Hampel, Anders Wallin, Lennart Minthon, Oskar Hansson, Kaj Blennow, Niklas Mattsson and Henrik Zetterberg
    Citation: Alzheimer's Research & Therapy 2017 9:87
  42. A reliable blood-based assay is required to properly diagnose and monitor Alzheimer’s disease (AD). Many attempts have been made to develop such a diagnostic tool by measuring amyloid-β oligomers (AβOs) in the...

    Authors: Seong Soo A. An, Byoung-sub Lee, Ji Sun Yu, Kuntaek Lim, Gwang Je Kim, Ryan Lee, Shinwon Kim, Sungmin Kang, Young Ho Park, Min Jeong Wang, Young Soon Yang, Young Chul Youn and SangYun Kim
    Citation: Alzheimer's Research & Therapy 2017 9:86
  43. The progression of mild cognitive impairment (MCI) to Alzheimer’s disease (AD) dementia can be predicted by cognitive, neuroimaging, and cerebrospinal fluid (CSF) markers. Since most biomarkers reveal compleme...

    Authors: Lutz Frölich, Oliver Peters, Piotr Lewczuk, Oliver Gruber, Stefan J. Teipel, Hermann J. Gertz, Holger Jahn, Frank Jessen, Alexander Kurz, Christian Luckhaus, Michael Hüll, Johannes Pantel, Friedel M. Reischies, Johannes Schröder, Michael Wagner, Otto Rienhoff…
    Citation: Alzheimer's Research & Therapy 2017 9:84
  44. Brain lesions in Alzheimer’s disease (AD) are characterized by Aβ accumulation, neurofibrillary tangles, and synaptic and neuronal vanishing. According to the amyloid cascade hypothesis, Aβ1-42 oligomers could...

    Authors: Jacques Hugon, François Mouton-Liger, Julien Dumurgier and Claire Paquet
    Citation: Alzheimer's Research & Therapy 2017 9:83
  45. Gene suppression approaches have emerged over the last 20 years as a novel therapeutic approach for the treatment of neurodegenerative diseases. These include RNA interference and anti-sense oligonucleotides, ...

    Authors: Rhia Ghosh and Sarah J. Tabrizi
    Citation: Alzheimer's Research & Therapy 2017 9:82
  46. Research has revealed that manifest Alzheimer’s disease (AD) dementia is preceded by preclinical and prodromal phases during which pathology is accumulating but function remains intact. This understanding and ...

    Authors: Michelle M. Nuño, Daniel L. Gillen, Kulwant K. Dosanjh, Jenny Brook, David Elashoff, John M. Ringman and Joshua D. Grill
    Citation: Alzheimer's Research & Therapy 2017 9:81
  47. The deposition of neurotoxic amyloid-β (Aβ) peptides in plaques in the brain parenchyma and in cerebral blood vessels is considered to be a key event in Alzheimer’s disease (AD) pathogenesis. Although the pres...

    Authors: Oliver Wirths, Susanne Walter, Inga Kraus, Hans W. Klafki, Martina Stazi, Timo J. Oberstein, Jorge Ghiso, Jens Wiltfang, Thomas A. Bayer and Sascha Weggen
    Citation: Alzheimer's Research & Therapy 2017 9:80